Skip to main content

Regeneron news and events in 2026

Regeneron is a biopharmaceutical organization that invents, develops, and commercializes medicines intended for individuals with serious diseases. The organization focuses its scientific efforts on several therapeutic areas, including metabolic diseases, ophthalmology, and rare diseases.

Public (REGN)Biotechnology Research10,000+ employeesregeneron.comLinkedIn

Get Regeneron's live signals in Claude or ChatGPT, or by API

AskWhat changed at Regeneron this week? Use Autobound signals for regeneron.com.
Dated updates
94
Last event
Oct 30, 2026
Open rolesSnapshot Nov 3, 2026
156
Latest SEC filing
Oct 30, 2026

Source: Autobound Signal API · 94 signals tracked for Regeneron · updated

Overview

Regeneron by topic

Latest events

Latest Regeneron events

  1. Revenue
    Regeneron Q3 Revenue Rises 36% to $5.12 BillionRegeneron Pharmaceuticals reported third-quarter 2026 revenue of $5.116 billion, up 36% year over year.
  2. Partnership
  3. Office expansion
  4. Investment
    REGN Becomes Final Major Drugmaker To Sign Trump’s Drug Pricing PledgeRegeneron committed more than $9 billion to U.S.-based manufacturing and research-and-development infrastructure investments over the coming years.
  5. New customer
    Sanofi expands its partnership with Regeneron in an $8 billion dealRegeneron will receive $1 billion upon signing and up to an additional $7 billion in future milestone payments from Sanofi as part of an expanded partnership.
  6. In development
  7. Earnings
    Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026Regeneron Pharmaceuticals will report its third quarter 2026 financial and operating results on October 30, 2026.
  8. In development
    Paroxysmal Nocturnal Hemoglobinuria Market Forecast Upto 2036: 5 Emerging Therapies Poised to Accelerate Market GrowthRegeneron Pharmaceuticals is developing Pozelimab + Cemdisiran, a potential therapy for paroxysmal nocturnal hemoglobinuria (PNH).
  9. Launch
    Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOPRegeneron Pharmaceuticals received FDA approval for its drug Pasatru (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva (FOP).
  10. Integration

Showing 10 of 31 events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Regeneron with the Signal API

One POST /v1/companies/enrich call with regeneron.com returns every signal type for Regeneron, each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'

Bulk data

Need these signals for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file).

Talk to sales

Same industry

Regeneron questions

What is the latest news on Regeneron?
On Oct 30, 2026, grafa.com reported: Regeneron Q3 Revenue Rises 36% to $5.12 Billion. This page tracks 31 news events for Regeneron since Nov 13, 2025, each with a date and a source link.
What is going on with Regeneron?
In the 90 days to Nov 4, 2026, Autobound tracked 12 news events, 1 10-Q filing, 3 8-K filings, 4 hiring snapshots, 37 signals for Regeneron. The newest story is from Oct 30, 2026 (Revenue), reported by grafa.com.
What else does Autobound track for Regeneron?
Beyond news and filings, Autobound lists 52+ signals for Regeneron from 7 sources: Glassdoor (15+), Website changes (15+), Patents (12), LinkedIn (4), Reddit (3), Podcasts (2), Web traffic (1). See the Regeneron signals page for the dated list.
Is Regeneron hiring right now?
Yes. As of Nov 3, 2026, Regeneron had 156 open roles, and Legal had the most with 15.

Page updated , the date of the newest row on this page.

Source. News, SEC filings (8-K, 10-K, 10-Q, Form D), hiring data and other signals (Reddit, podcasts, Glassdoor, reviews, social posts, patents, web traffic) from the Autobound Signal API.

Method. Stories are grouped when they report the same event within 14 days. Rows that do not name the company are removed. Each row links its source.

Data as of .

How this data is built →Get it from the Signal API →